Skip to main content
. 2021 Aug 17;11:633430. doi: 10.3389/fonc.2021.633430

Figure 1.

Figure 1

(A) Analysis of HOXA5 mRNA levels (log2) in WHO grades II to IV gliomas from TCGA and CGGA. (B) Analysis of HOXA5 mRNA levels (log2) in various cancer types. (C) The expression level of HOXA5 in different age groups in pan-glioma analysis in TCGA and CGGA data sets, and in GBM patients in TCGA microarray data set. (D) HOXA5 was upregulated in the IDH mutant gliomas in TCGA data set, in the IDH mutant GBM in TCGA microarray data set and in both the IDH mutant gliomas and GBM alone in CGGA data set. (E) HOXA5 was upregulated in the 1p19q codeletion in pan-gioma analysis in both TCGA and CGGA data sets. (F) HOXA5 was upregulated in the methylated gliomas in TCGA data set. NS, Not Statistically Significant; *P < 0.05; **P < 0.01; ***P < 0.001.